RM-END / Endocrine and peptide-hormone analogs
Octreotide
Also known as: Octreotide acetate · Somatostatin analog
Grade describes the published research on the molecule. It is not a quality score, a safety score, or a release state.
What this is
Octreotide is a synthetic cyclic analog of somatostatin. Product form matters: solution, depot and other presentations have different formulation and release records.
Evidence position
FDA-labeled comparators support Grade A for the regulated products.
What the record does not establish
Approval of one octreotide presentation does not authenticate a different form or third-party sample.
Sources
- 01Sandostatin injection prescribing informationDailyMed / U.S. National Library of Medicine
- Shows
- U.S. label for a defined octreotide acetate presentation
- Does not show
- Does not qualify a different formulation, depot or source
External database index
LIVE DATABASE INDEX / SEPARATE FROM CURATED EVIDENCE
Records below come directly from public scientific databases. They help find relevant material, but do not affect the evidence grade until they are matched to the molecule and added to the curated source list.
PUBCHEM / IDENTITY
Octreotide
- CID
- 448601
- Formula
- C49H66N10O10S2
- Mass
- 1019.2
PUBMED / FOUND RECORDS
- Octreotide.Neonatal network : NN / 2006 Sep-OctPMID 16989134 / DOI 10.1891/0730-0832.25.5.365
- Use of octreotide for the treatment of protein-losing enteropathy in dogs: Retrospective study of 18 cases.Journal of veterinary internal medicine / 2024 Jan-FebPMID 38038236 / DOI 10.1111/jvim.16966
- Octreotide and Octreotide-derived delivery systems.Journal of drug targeting / 2023 JulPMID 37211679 / DOI 10.1080/1061186X.2023.2216895
- Octreotide in hyperinsulinism.The Annals of pharmacotherapy / 1997 FebPMID 9034427 / DOI 10.1177/106002809703100217
- Octreotide-induced bradycardia.Pharmacotherapy / 1998 Mar-AprPMID 9545165
CLINICALTRIALS.GOV / FOUND RECORDS
- Comparison of 2 Days Versus 5 Days of Octreotide After Endoscopic Therapy in Preventing Early Esophageal Varices Rebleed : A Randomized Controlled StudyUNKNOWN / PHASE4 / Tanta UniversityNCT05199038 / DIRECT intervention MATCH: Octreotide
- Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)COMPLETED / PHASE2 / Camurus ABNCT02299089 / DIRECT intervention MATCH: Octreotide
- Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine TumorACTIVE_NOT_RECRUITING / PHASE3 / National Cancer Institute (NCI)NCT00569127 / DIRECT intervention MATCH: Octreotide
- Acute Application of Pegvisomant and Octreotide in AcromegalyCOMPLETED / PHASE4 / Ludwig-Maximilians - University of MunichNCT00595140 / DIRECT intervention MATCH: Octreotide
- Octreotide in Treating Patients With Locally Advanced or Metastatic Liver CancerCOMPLETED / PHASE2 / UNC Lineberger Comprehensive Cancer CenterNCT00257426 / DIRECT intervention MATCH: Octreotide